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Abstract—The priority direction of the domestic economy is 
the sphere of public security. In a stable economy, the state is 
able to provide the population with all the necessary means to 
preserve life and health. Data allow sequence of events of 
scientific ideas and legal problems to be established as a result of 
studies of the materials. The implementation of reforms has 
allowed the country to improve the quality of medicines and 
access to medicines. The Russian stood at the dawn of a period 
that has seen the restoration and accomplishment. However, they 
have been disrupted as a result of political and socio-economic 
changes. The pharmaceutical sector is a priority industry. The 
concept of sustainable development has the potential to set the 
framework for improve the pharmaceutical sector. Societies must 
change the legal regulation mechanism. Those measures should 
include the prevalence of the information and 
telecommunications technologies. Since the Internet 
opportunities for the exchange of experience and technologies in 
the world community, including in the pharmaceutical sector, 
have expanded. 
Keywords—priority areas, priority industry, sustainable 
economy, legal issues, pharmaceutical sector, medicines 
I.  INTRODUCTION 
The fundamental component of the health care system is 
medicines. They are necessary to provide the population with 
high-quality medical care. This guarantees the health and free 
qualified medical care. Medicines are diagnostic, therapeutic, 
prophylactic and rehabilitative medicinal drug. The 
pharmaceutical industry is the basis for their creation. Its 
construction is based on a system of legal, socio-economic and 
medical measures. They should contribute to raising the level 
of protection and preservation of public health. 
The study of the evolution of sustainable development of 
pharmaceutical sector has been the subject of many articles, 
including by foreign authors. For example, about 
pharmaceutical medicine and law [1-3], pharmaceuticals [4-
10], pharmacy users [11], pharmaceutical formulation 
science [12-14], pharmaceutical documentation [15], 
pharmaceutical policy [16-20] and others. However, there is 
no comprehensive approach to the research not yet. 
The importance of the information and 
telecommunications network "Internet" as a dissemination 
vehicle is constantly increasing. There are opportunities for 
sharing experiences and technologies in the world community, 
including in the pharmaceutical sector. This made it possible 
not only to improve medicines, but also to create new ones. 
For sustainable development and effective activity were 
created: World Health Organization, The Global Health 
Workforce Alliance, developed the Country Coordination and 
Facilitation, The International Medical Cluster and etc. With 
the help of the Internet, all people around the world have 
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access to qualified health workers and the ability to obtain the 
medicine they need to treat. 
II. MATERIALS AND METHODS 
The methodological basis of the study consisted of general 
scientific and private scientific methods such as abstracting, 
concretization, content analysis, formal legal, comparative 
legal. The research materials are presented by regulatory legal 
acts, law enforcement practice and doctrinal sources. The 
evaluation of the legal regulation of pharmaceutical sector 
identified challenge, based on an overall data. 
III. RESULTS 
In the Russian Socialist Federative Soviet Republic 
(hereinafter the RSFSR), the legal regulation of the 
pharmaceutical sector was carried out through legal and 
professional regulation, such as the control of quality, 
production, development, storage, transportation, packaging, 
sales, destruction of medicines, pricing, and professional 
requirements for specialists. 
Pharmaceutical plants in Russia appeared in the second 
half of the 19th century. They produced galenicals and 
pharmaceutical goods until 1917 [21]. Synthetic organic 
medicines and alkaloids were not produced, and the need for 
them was satisfied by import. Enterprises were created by 
private individuals and some public organizations, for 
example, the Red Cross Society. However, with a significant 
lack of raw materials and qualified personnel, this did not 
satisfy the country's needs. The production of medicines, both 
before the formation of the RSFSR and immediately after, was 
carried out by pharmacies and industrial enterprises. 
The enterprises of the pharmaceutical industry were 
engaged in the production of perfumes, cosmetics and 
household goods, the bottling of vinegar essence, weighed out 
pepper, soda and laundry blue. The products were sold 
through the state system of sales and supply, medical supply 
systems on transport, etc. Direct dispensing of medicines to 
consumers was carried out through the pharmacy network. 
The medicines were both packaged and dosed. 
In the first years of Soviet state, the task of free of charge 
qualified medical care was difficult because of a destroyed 
healthcare infrastructure and pharmaceutical business. As a 
result effort was expended in the conduct to create a 
regulatory framework in order to improve society [13, p. 470]. 
In 1917 the regulation on workers' control was enacted, 
introducing working control over the production and 
distribution of products. The nationalization of individual 
industrial complexes is ensured by the decree of the Council 
of People's Commissars of June 28, 1918 "About the 
Nationalization of the Largest Enterprises ..." In 1919, twenty 
two of the largest plants and the main chemical industry were 
nationalized. 
The All-Russian Congress of Pharmaceutical Subdivisions 
in 1919 was decided to make medical assistance quick, 
affordable and rational. Over the past years, nine new large 
plants have been established to the forty seven liquidated 
pharmaceutical enterprises base. The increasing concentration 
of the pharmaceutical industry was produced at the beginning 
by the New Economic Policy in the creation of trusts. 
With the formation of the USSR, new pharmaceutical 
enterprises and plants were opened, research institutions were 
organized, control and analytical laboratories were operating, 
and a pharmacopoeia commission was being created. The 
volume of production was able to expand in 1924 through 
profiling of products by a related technological process and 
the exclusion of non-medical products from their range. 
The Supreme Council of the National Economy of the 
USSR developed a plan for the development of the 
pharmaceutical industry for 1925/26 - 1929/30. They took into 
account the needs of the health authorities and the population 
in medicines. The five-year plans of binding on business 
entities made it possible to build management on the basis of 
state plans for economic and social development. 
A policy was pursued to bring production, methods of 
control and price unification into uniformity. In the two five-
year plans, especially in the second, the medical industry 
showed exceptional growth. About 400 items of new products 
were mastered and produced. The production of over 150 
drugs was delivered. A number of substitutes for imported 
medicines were released, for example, acrychin, novocaine, 
anestezin and others. The development of pharmaceutical 
science and industry, the achievements of medical practice 
allowed the production and use of complex synthetic drugs for 
the treatment and prevention of diseases in both humans and 
animals. Each new pharmaceutical product authorized for 
production and release was entered into a special register of 
new pharmaceutical products authorized for production and 
release in the USSR, according to the Decree of the Council of 
People's Commissars of the USSR of 16.11.1937 N 2038 
“About the Production and Output of New Pharmaceutical 
Products”. The system of the production of medicines from 
medicinal plants was expanded. 
The creation of a solid research base became an important 
factor in the organization of production, in particular in the 
introduction of new medicines and the development of new 
technologies. To strengthen the connection between science 
and practice, the All-Union Scientific and Pharmaceutical 
Society was created in 1949, and in 1958 the All-Russian 
Scientific Society of Pharmacists. The structure of industry 
and construction management is based on the territorial 
principle [14]. 
The pharmaceutical industry was part of the material base 
on which health authorities relied to maintain public health 
and increase the average life expectancy of citizens. All 
actions were aimed at implementing the Decree of the Central 
Committee of the CPSU and the Council of Ministers of the 
USSR dated 01/14/1960 No. 58 "About Measures of Further 
Improvement of Medical Services and Health Protect of the 
Population of the USSR" [22]. The restoration and growth of 
pharmaceutical sector in the country was due to the creation of 
research and production complexes and research and 
production associations of the pharmaceutical industry. 
The control procedure for production was established by 
the order of the USSR Ministry of Health of 10/15/1976 No. 
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987. In accordance with which the high quality of medicines 
was ensured by: strict compliance with the requirements of 
regulatory and technical documentation; production control; 
compliance with a number of preventive measures. 
The requirements for the storage and transportation of 
medicines and packaging materials were enacted at enterprises 
and organizations of the pharmaceutical industry. Premises 
intended for storage should have been equipped with 
everything necessary in order to ensure the preservation of the 
initial medicines and packaging materials. Regulatory and 
technical documentation established the requirements for 
containers and packaging for various medicines. The 
instruction of incoming quality control in production was 
approved in 1986. They established a uniform procedure for 
monitoring production, as well as the quality of raw materials. 
The intention was to prevent the production of products that 
do not meet the requirements of the current regulatory and 
technical documentation, and prevent the use of low-quality 
raw materials in the production. Factories and enterprises were 
supposed to use raw materials in production, which passed 
quality control. They were established by scientific and 
technical documentation, the State Pharmacopoeia of the 
USSR, State All-Union standard and pharmacopoeia items. 
The beginning of economic reforms in Russia was 
accompanied by the emergence of private property, a change 
in the system of procurement of medicines. Decree of the 
Council of Ministers of the USSR of February 18, 1988 No. 
236 "About Measures to Increase the Medicines, their Full 
Provision for the Population, Medical Institutions and the 
National Economy in 1988-1995" became impossible to 
implement. 
The legal framework allowed the development and 
improvement of the pharmaceutical sector in the RSFSR and 
the USSR. The level of production increased due to the 
intensification and reconstruction of existing enterprises, the 
mechanization of labor-intensive processes and the 
improvement of production technologies. Over the years of 
nine five-year plans, the growth of pharmaceutical sector in 
the country was due to the creation of a powerful 
constitutional-legal and material-technical base, the 
organization of  research and production complexes and  
research and production associations of the pharmaceutical 
industry. The development of Soviet medical science 
improved the quality and timeliness of the provision of 
medical care to citizens and the effectiveness of sanitary and 
preventive measures. 
The Federal Law "About Medicines" came into force in 
1998. It reinforced the provisions on the organization of 
production and state control of the quality, effectiveness and 
safety of medicines. The legal term “Production of Medicines” 
was approved, which was understood as the serial production 
of medicines in accordance with the rules for the organization 
of production and quality control of medicines, approved by 
the federal body for quality control of medicines. For 
production, enterprises must have a license. 
It was forbidden to manufacture medicines that did not 
pass state registration or in violation of the rules for 
organizing the production and quality control of medicines. 
The production of patented medicines and their sale are 
carried out in accordance with the patent legislation of the 
Russian Federation. 
Now the Federal Law “About Circulation of Medicines” is 
in force, according to which the production of medicines must 
comply with the requirements of the rules of good 
manufacturing practice. This wording appeared in edition No. 
17 of 07/13/2015, despite the fact that the Order of “Good 
Manufacturing Practice” was approved by order of the 
Ministry of Industry and Trade of Russia dated June 14, 2013 
No. 916. Prior to this, the rules for the organization of 
production and quality control of medicines were in force. The 
Agreement on common principles and rules for the circulation 
of medicines within the framework of the Eurasian Economic 
Union, including decision of the Council of the Eurasian 
Economic Commission dated 03.11.2016 No. 77 on the rules 
of good manufacturing practice, was also applied. The policy 
of import substitution is being re-established. There is an 
emerging single economic space [18]. 
Establishing priority areas of a sustainable development of 
became a new mark in pharmaceutical sector development. 
The priority areas for the development of the pharmaceutical 
industry of the Russian Federation were approved in 2020 by 
the order of the Government of 06.06.2020 N 1512-r. This 
includes: introduction of scientific and technological 
competencies; formation of a high-performance export-
oriented sector; introduction of digital technologies; 
production of high-quality, effective and safe pharmaceutical 
products; prevention of circulation of falsified, counterfeit and 
non-conforming products; development of the national 
pharmaceutical industry; provision of the population with vital 
and essential medicines. The priority product groups for the 
pharmaceutical industry by 2035 includes vital and essential 
medicines; immunobiological drugs. The functioning and 
development of the pharmaceutical sector is influenced by 
medicines patent laws; test standards; marketing rules for 
finished products. 
The import substitution policy is carried out in relate to 
vital and essential medicines. Such medicines are included in 
the list. The list is annually approved by the Government of 
the Russian Federation for the purpose of state regulation of 
prices for medicines. Medicines are under international non-
proprietary names. They cover most types of health care under 
the state guarantee. Import substitution rules have deficiency 
of law and come into conflict with the federal law on the 
contract system. High-quality foreign medicines began to 
leave from the Russian market. The medicines procurement 
system itself requires modernization too.  
During a pandemic priorities have shifted. Much attention 
has been devoted prevention, diagnosis and treatment of new 
coronavirus infection (COVID-19). A duty-free import regime 
was introduced on goods to prevent coronavirus infection, for 
example, personal protective equipment, vaccines, syringes, 
disinfectants and other goods.  The medicines are being 
patented.  
The problems of organizing pharmaceutical sector and 
providing the population with affordable and high-quality 
medicines remain unresolved. There was a need not only for 
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adequate legislative regulation, but also for encourage 
production [19].  
In this regard, it is worth creating an international medical 
cluster, on the basis of which not only the exchange of 
experience, but also technologies will take place, looks 
promising. 
IV. DISCUSSIONS 
Studying the aspects of the regulation of the 
pharmaceutical sector allows us to single out several key 
problems requiring further solutions. The development of the 
pharmaceutical sector requires not only a stable economic 
base, but also an exchange system. Firstly, scientific institutes 
must be explicitly included in the structure of pharmaceutical 
plants. The creation of research and production complexes for 
the production of medicines, the so-called "science-
production-practice" system will result in the development and 
introduction of new medicines into circulation. This complex 
will allow quickly taking out a patent and implementing 
medicines in practice. Secondly, it is worth considering the 
foreign experience in the production of medicines, 
specifically, the establishment of tax benefits for research 
costs; reimbursement of a portion of the costs of drug 
development; marketing exclusivity; having priority 
consideration for authorizing the sale of a number of essential 
medicines, especially expensive ones. Perhaps a number of 
such economic incentives, enshrined in law, will improve the 
pharmaceutical sector. This will lead to an improvement in the 
life and health of the country's population. 
V. CONCLUSION 
The mechanism of drug circulation assumed their quality, 
effectiveness and safety. Pharmaceutical activity is designed 
to protect the fundamental human values - the life and health 
of the population. The creation of research and production 
complexes and the introduction of such changes into 
legislation, in our opinion, is one of the most effective means 
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